SCHEMBL6844946

SCHEMBL6844946

Cc1csc(-c2cc(O)c3ccc(O)c(Cl)c3n2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.39
ADORA2A P29274 5/20 0.38
CYP2E1 P05181 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2A6 P11509 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2B6 P20813 1/20 0.35
PLAU P00749 1/20 0.35
SRC P12931 1/20 0.34
CDK2 P24941 1/20 0.34
ZAP70 P43403 1/20 0.34
SYK P43405 1/20 0.34
MIF P14174 1/20 0.34
RAB9A P51151 2/20 0.34
MAPT P10636 3/20 0.33
CYP19A1 P11511 2/20 0.33
ESR2 Q92731 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6844911 0.86 ADORA2A (0.35) PDE10AADORA2ACYP2E1CYP3A4CYP2A6
SCHEMBL313767 0.86 MAPT (0.39) PDE10AADORA2ACYP2E1CYP3A4CYP2A6
SCHEMBL15215571 0.85 ADORA2A (0.37) PDE10AADORA2ACYP2E1CYP3A4CYP2A6
SCHEMBL10221665 0.83 TYK2 (0.32) CYP19A1
SCHEMBL8135887 0.81 PDE10A (0.34) PDE10AADORA2ACYP3A4CYP2C9SRC
SCHEMBL3625504 0.78 MAPT (0.40) PDE10AADORA2ACYP2E1CYP3A4CYP2A6
SCHEMBL6844944 0.77 MAPT (0.37) CYP3A4CYP2C9RAB9AMAPTCYP19A1
SCHEMBL10250159 0.76 PTGES (0.37) SMPD1
SCHEMBL13090548 0.73 MAPT (0.40) PDE10AADORA2ACYP2E1CYP3A4CYP2A6
SCHEMBL315199 0.73 ALDH1A1 (0.37) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011017389-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV IDENIX PHARMACEUTICALS, INC. (US) 2011-02-10 WO disclosed